Chemotherapy-Induced Peripheral Neuropathy (CIPN) – Pipeline Review, 2019

Peripheral neuropathy refers to the condition that arises from the damage of the peripheral nerves. These nerves are responsible for transmitting sensation, controlling movements of hands and legs, and controlling the bowel and bladder. The drugs used during chemotherapy for the treatment of cancer can cause peripheral nerve damage leading to chemotherapy-induced peripheral neuropathy. The drugs which can likely cause chemotherapy-induced peripheral neuropathy are oxaliplatin, docetaxel, vincristine, bortezomib, and others. Also, patients having a history of diabetes, preexisting peripheral neuropathy, or vitamin deficiencies, are more susceptible to chemotherapy-induced peripheral neuropathy.

The symptoms of chemotherapy-induced peripheral neuropathy are tingling, pain, decreased sensation, muscle weakness, and others. Current treatment of chemotherapy-induced peripheral neuropathy includes the use of antidepressants, anti-seizure medications, analgesics such as opiate drug, and others. Neuromodulation therapy can also be used for the treatment of chemotherapy-induced peripheral neuropathy.

The increasing prevalence of cancer and prominent use of chemotherapy as the first line of treatment is increasing the incident cases of chemotherapy-induced peripheral neuropathy. This has accelerated the clinical study for the development of an effective drug for the treatment of chemotherapy-induced peripheral neuropathy by pharmaceutical companies and research institutes. For instance; PledPharma AB, a pharmaceutical company, is conducting Phase 3 clinical trials on Calmangafodipir for the treatment of patients with chemotherapy-induced peripheral neuropathy.

At present, around 40% of the pipeline candidates for chemotherapy-induced peripheral neuropathy are in phase 2 clinical stage. More than half of the studies are sponsored by research institutes.

Report Description

The report on ‘Chemotherapy-Induced Peripheral Neuropathy (CIPN) – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Chemotherapy-Induced Peripheral Neuropathy (CIPN). The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Chemotherapy-Induced Peripheral Neuropathy (CIPN).

The report on ‘Chemotherapy-Induced Peripheral Neuropathy (CIPN) – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

• Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary